Proactive Investors
28 Sept 2026, 17:36 UTC · 2h ago
Verdict
Headline leans bullish. We score KOD +1.00 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Zenkuda and tabirafusp-ted met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration.
Newannouncement published Monday 28 Sep 2026
So whatSuccess in a Phase III pivotal trial significantly increases the probability of FDA approval and future peak sales estimates.
More positive than 99% of claims this week
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Kodiak Sciences plans to submit Zenkuda's biologics license application in the fourth quarter of 2026 for three different conditions.
Newannouncement published Monday 28 Sep 2026
So whatThe Q4 2026 filing timeline sets a concrete horizon for potential commercialization and revenue generation in 2027.
More positive than 98% of claims this week
Among Zenkuda patients, 54% reached 24-week dosing intervals at one year under strict retreatment criteria.
Newannouncement published Monday 28 Sep 2026
So whatIncreased dosing intervals provide a competitive advantage over aflibercept, potentially driving higher market share upon launch.
More positive than 87% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Shares surged over 162% after two experimental drugs met primary endpoints in a phase III trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1h ago
Reuters
8h ago
+179.0%
Price agrees with the score
$90.26 vs $32.35 close before publication (Sep 25) · not market-adjusted
KOD chart →
